Brief: Allurion Reports Positive Topline Results From AUDACITY Trial
08/01/2025 14:04
Jan 8 (Reuters) - Allurion Technologies Inc ALUR.N :
* ALLURION ANNOUNCES POSITIVE TOPLINE RESULTS FROM AUDACITY
TRIAL
* ALLURION TECHNOLOGIES INC - AUDACITY TRIAL ACHIEVES
RESPONDER
RATE CO-PRIMARY ENDPOINT
* ALLURION TECHNOLOGIES INC - SERIOUS ADVERSE EVENTS RATE IN
ALLURION BALLOON SUBJECTS AT 3.1%
* ALLURION TECHNOLOGIES INC - BALLOON SUBJECTS SHOW GREATER
WEIGHT
LOSS AT 48 WEEKS VERSUS CONTROL SUBJECTS
* ALLURION: FOURTH AND FINAL MODULE OF PMA SUBMISSION
INCLUDING
AUDACITY TRIAL DATA PLANNED FOR 2025
Source text: urn:newsml:reuters.com:*:nBw8JCXSGa
Further company coverage: ALUR.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allurion Technologies
See all newsBrief: Allurion Technologies Inc - Sees Growing Demand From Patients Discontinuing Glp-1 Therapy
Brief: Allurion Intends To Appeal NYSE Notice Of Delisting, Execute Plan To Regain Compliance, And Expects To Continue Trading On NYSE
Brief: NYSE To Commence Delisting Proceedings Against Allurion Technologies, Inc.
Allurion rises on plan to offer discounted weight-loss drug Mounjaro in Argentina
Allurion rises after strong weight-loss data from combination therapy